Welcome to our dedicated page for Opko Health news (Ticker: OPK), a resource for investors and traders seeking the latest updates and insights on Opko Health stock.
OPKO Health, Inc. (NASDAQ: OPK) is a multinational biopharmaceutical and diagnostics company. This news page aggregates press releases and announcements related to OPKO’s pharmaceutical, diagnostics and collaboration activities, offering a focused view of how the company communicates business developments to the market.
Readers can find news about OPKO’s quarterly business highlights and financial results, as reported in its earnings press releases and accompanying conference call information. These updates typically summarize segment performance across pharmaceuticals and diagnostics, and describe notable transactions such as the sale of certain BioReference Health oncology and related clinical assets to Labcorp.
The news feed also reflects OPKO’s biopharmaceutical pipeline and research collaborations. Items include disclosures from ModeX Therapeutics, an OPKO Health company, on multispecific antibody programs like MDX2001 and MDX2004, as well as collaboration agreements with partners such as Regeneron Pharmaceuticals and Merck. In addition, OPKO reports on joint work with Entera Bio on oral GLP-1/glucagon and GLP-2 tablet candidates and on regulatory milestones for diagnostics such as the 4Kscore® Test.
Investors and observers can follow OPKO’s participation in healthcare investor conferences, where management holds one-on-one meetings and public discussions, as well as announcements about share repurchase authorizations and capital structure transactions. By reviewing this page regularly, users can see how OPKO presents its operational progress, collaborations and diagnostics initiatives over time.
OPKO Health (NASDAQ: OPK) subsidiary ModeX Therapeutics began dosing patients in a Phase 1 safety and tolerability study of MDX2003, a first‑in‑class tetraspecific T‑cell engager for relapsed or refractory B‑cell lymphoma, on April 22, 2026.
The drug targets CD19 and CD20 on tumor cells plus CD3 and CD28 on T cells; preclinical data and dose‑selection analyses were presented at ASH 2025 and ESMO TAT 2026.
OPKO Health (NASDAQ: OPK) will report first quarter 2026 operating and financial results for the period ended March 31, 2026 after market close on April 28, 2026.
Management will host a conference call and live audio webcast on April 28 at 4:30 p.m. Eastern to discuss results and financial guidance. Telephone replay and webcast replay will be available through early May.
ModeX Therapeutics (NASDAQ: OPK) initiated dosing in a Phase 1 trial of MDX2301, a tetravalent bispecific multispecific antibody designed to neutralize all known SARS-CoV-2 variants. The randomized, double-blind, placebo-controlled, dose-escalation study will assess safety and tolerability across intravenous, intramuscular and subcutaneous routes in up to 80 participants.
The trial is federally funded by HHS/ASPR/BARDA under contract 75A50123C00056 and will also evaluate pharmacokinetics, anti-drug antibodies and neutralizing activity.
OPKO Health (Nasdaq: OPK) will participate in the Jefferies Biotech on the Beach Summit March 10-11, 2026, at 1 Hotel South Beach in Miami. Management will hold one-on-one investor meetings on Wednesday, March 11. Investors should contact their Jefferies representative to schedule meetings.
OPKO Health (NASDAQ: OPK) reported Q4 2025 results and 2026 guidance on Feb 26, 2026. Consolidated Q4 revenues were $148.5M vs $183.6M year-ago; Q4 net loss was $31.3M (‑$0.04 per share). Cash and equivalents were $369.1M at year-end. Key pipeline and partnerships: Regeneron multispecific collaboration (>$1B potential, >$200M program milestones), Merck EBV vaccine Phase 1 completed, BARDA-supported COVID antibody Phase 1 planned Q2 2026.
OPKO Health (NASDAQ: OPK) will report operating and financial results for the three and 12 months ended December 31, 2025, after U.S. markets close on February 26, 2026.
Senior management will host a business update, discuss results and provide financial guidance on a conference call and live webcast at 4:30 p.m. ET. Registration, dial-in numbers, webcast links and replay details are available for investors; telephone replay accessible through March 5, 2026.
OPKO Health (NASDAQ: OPK) and Entera Bio (NASDAQ: ENTX) expanded their collaboration to advance a first-in-class oral long-acting PTH (LA-PTH) once-daily tablet for hypoparathyroidism. The program is 50/50 owned and cost-shared, with an IND filing targeted for late 2026 after favorable PK/PD preclinical data.
The companies maintain a 60/40 ownership and cost split (OPKO/Entera) for the oral oxyntomodulin (OXM) program, with injectable Phase 1 data expected by late 2026. Steve Rubin joins Entera's board as Gerry Ostrov steps down.
OPKO Health (Nasdaq: OPK) said its management team will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, held January 12-15, 2026. Management will host one-on-one investor meetings and take part in a fireside chat on Wednesday, January 14, 2026 at 1:30 p.m. PT. The fireside chat will be webcast live and available for replay in the Investors section of OPKO Health's website.
OPKO Health (Nasdaq: OPK) will participate in the Piper Sandler 37th Annual Healthcare Conference in New York City from December 2–4, 2025. Management will hold one-on-one investor meetings and appear in a fireside discussion on December 3, 2025 at 12:00 p.m. ET. Investors who want meetings are instructed to contact their Piper Sandler representative to schedule.
OPKO Health (NASDAQ: OPK) reported third-quarter 2025 results and business highlights on October 29, 2025, including a multi‑program research collaboration with Regeneron using ModeX MSTAR, with potential program milestones >$200M each and overall collaboration value potentially exceeding $1 billion. OPKO completed the sale of BioReference oncology assets to Labcorp for $225 million (including up to $32.5M earnout) and received $173.3M cash at closing. Consolidated Q3 revenue was $151.7M (down from $173.6M); operating income was $48.1M; net income was $21.6M ($0.03 diluted) which included a $101.6M gain on the asset sale. Cash and equivalents were $428.9M; $73.8M of share repurchases completed, $126.2M remaining.